Stories

The UK government passed the Tobacco and Vapes Bill to create a smoke-free generation, prohibiting tobacco sales to those born after 2009. Critics argue the law is illiberal and targets smoking cessation aids. While aiming to reduce smoking-related illnesses, concerns arise about illegal tobacco trade and the impact on vaping, a popular smoking alternative. Advocates suggest following Sweden's model by promoting safer nicotine products rather than enforcing bans. The bill faces criticism for potentially causing more harm than good, as it restricts vaping promotion. Monitoring the law's effects on smoking trends and public health remains crucial.

Australia’s strict tobacco and vaping policies are increasingly linked to the rapid growth of an illicit nicotine market. Insights from recent discussions suggest that heavy taxation and prohibitive regulations have shifted a large share of demand into criminal channels. Estimates indicate that a significant portion of tobacco sales—and the vast majority of vaping products—now circulate outside the legal system. Experts argue that these conditions have created lucrative opportunities for organised crime, which has stepped in to meet persistent consumer demand.The situation highlights concerns that overly restrictive policies may reduce legal access without eliminating use. More broadly, it raises questions about whether prohibition-focused approaches can effectively control nicotine markets without unintended consequences.

Debate over heated tobacco products is intensifying as regulators and public health advocates interpret the evidence in different ways. Authorisation decisions by the U.S. Food and Drug Administration have recognised that some products can reduce exposure to harmful chemicals compared to cigarettes. This distinction is based on extensive scientific review, highlighting the role of combustion—not nicotine itself—as the primary source of harm. However, critics argue that parts of the public health community continue to downplay or reject these findings, creating confusion around relative risk. Such messaging may discourage smokers from switching to potentially less harmful alternatives, undermining harm reduction efforts. The debate ultimately reflects a wider divide between evidence-based regulatory assessments and broader public health narratives on tobacco and nicotine.

Research supports that vaping aids smoking cessation and exposes users to fewer harmful chemicals. However, public perception often portrays vaping as equally or more harmful than smoking, leading to misinformation. Despite evidence demonstrating vaping's benefits for quitting smoking, public understanding continues to worsen. Healthcare professionals also exhibit misconceptions about the risks of vaping versus smoking, impacting their advice to patients. High-profile health scares, like EVALI and "popcorn lung," contribute to negative perceptions of vaping. A lack of awareness about programs promoting vaping as a quit-smoking aid highlights the importance of effective communication. Ultimately, misconceptions about vaping's risks may hinder smoking cessation efforts and regulatory decisions.

Europe’s approach to nicotine regulation is increasingly being compared to Australia’s strict and controversial policies. Critics warn that heavy restrictions on vaping and alternative products risk repeating what they describe as a “policy failure” seen in Australia. Evidence from that model suggests that limiting access to safer alternatives can drive consumers toward black markets rather than reduce nicotine use. There are also concerns that such measures may undermine harm reduction efforts by discouraging smokers from switching away from combustible cigarettes. Supporters of a more balanced approach argue that regulation should be guided by scientific evidence rather than prohibition. The debate highlights broader tensions over whether Europe should prioritise strict control or pragmatic harm reduction in shaping future public health policy.

Concerns are growing over how decisions on flavoured vaping products are being made within the United States regulatory system. Discussion around U.S. Food and Drug Administration highlights claims that scientific evidence supporting certain products may not be fully reflected in final decisions. Experts point to potential “blind spots” in how data is interpreted, particularly when it comes to evaluating the role of flavours in helping adults switch from smoking. The debate raises questions about consistency between the agency’s scientific mandate and its regulatory outcomes. Critics argue that overly cautious or restrictive decisions could limit access to alternatives for smokers.At the same time, the controversy reflects broader tensions over how evidence, risk and public health priorities are balanced in nicotine policy.

A new platform, THR Global, highlights real-life testimonies of individuals worldwide who switched to safer nicotine products for harm reduction. It aims to empower consumers often excluded from media and policy discussions. Founded by Kurt Yeo, the website emphasizes the importance of consumer voices in decision-making and tobacco harm reduction advocacy. Testimonies share personal journeys of quitting smoking with products like vapes or snus. THR Global provides a vital resource to amplify these voices and advocate for harm reduction principles globally. Encouraging more participation is crucial for the platform's success in promoting evidence-based tobacco harm reduction solutions.

France’s decision to ban nicotine pouches is triggering a growing legal and political dispute within the European Union. New rules go beyond sales restrictions, criminalising even the possession and use of these products, including those legally purchased in other EU countries. Members of the European Parliament are now questioning whether the policy violates single market principles, particularly the free movement of goods and people. The case highlights tensions between national public health measures and EU-wide legal frameworks designed to ensure consistency across member states. Critics argue that such sweeping restrictions risk creating fragmentation within the EU, where the same product is legal in one country but criminal in another. The dispute ultimately raises broader questions about how far individual countries can go in regulating nicotine products within a shared European market.

Spain is moving to tighten control over how vapes and nicotine pouches are sold, signalling a stricter regulatory approach. Proposed measures would limit sales to authorised outlets such as specialised shops, while restricting availability in general retail and online channels. The changes are intended to address what policymakers describe as a lack of oversight in the current market and to reduce youth access. At the same time, critics argue that narrowing distribution channels could make these products less accessible to adult smokers seeking alternatives.The debate reflects broader tensions between stricter regulation and harm reduction strategies across Europe.It also raises questions about whether limiting access could have unintended consequences for smoking rates and consumer behaviour.

CAPHRA urges responsible communication regarding smoking and vaping, emphasizing the need for balanced health information. While acknowledging vaping risks, CAPHRA highlights the importance of relative risk compared to smoking. Emotionally charged health stories online can lead to fear-based narratives, affecting public health. The organization advocates for youth protection, product standards, and informed decision-making for smokers considering lower-risk alternatives. CAPHRA emphasizes discouraging vaping among young individuals, encouraging smokers to quit, and providing access to regulated alternatives. The key message is promoting informed choices based on relative risks and steering away from fear-driven messaging.